Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial

被引：0
|
作者：
Binghe Xu
Zefei Jiang
Zhimin Shao
Jiayu Wang
Jifeng Feng
Shuping Song
Zhendong Chen
Kangsheng Gu
Shiying Yu
Yiping Zhang
Chuan Wang
Fengchun Zhang
Junlan Yang
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Medical Oncology, Cancer Hospital and Institute
[2] Beijing 307 Hospital,Cancer Hospital and Shanghai Cancer Institute
[3] Fudan University,First Affiliated Hospital
[4] Jiangsu Cancer Hospital,Tongji Hospital
[5] Shandong Cancer Hospital,Affiliated Union Hospital
[6] Anhui Medical University,Renji Hospital
[7] Huizhong Science and Technique University,undefined
[8] Zhejiang Cancer Hospital,undefined
[9] Fujian Medical University,undefined
[10] Shanghai Jiaotong University,undefined
[11] 301 Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Advanced breast cancer; Anastrozole; Arimidex; China; Faslodex; Fulvestrant; Oestrogen receptor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：223 / 230
页数：7
相关论文
共 50 条
  • [1] Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial
    Xu, Binghe
    Jiang, Zefei
    Shao, Zhimin
    Wang, Jiayu
    Feng, Jifeng
    Song, Shuping
    Chen, Zhendong
    Gu, Kangsheng
    Yu, Shiying
    Zhang, Yiping
    Wang, Chuan
    Zhang, Fengchun
    Yang, Junlan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 223 - 230
  • [2] Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
    Robertson, John F. R.
    Bondarenko, Igor M.
    Trishkina, Ekaterina
    Dvorkin, Mikhail
    Panasci, Lawrence
    Manikhas, Alexey
    Shparyk, Yaroslav
    Cardona-Huerta, Servando
    Cheung, Kwok-Leung
    Philco-Salas, Manuel Jesus
    Ruiz-Borrego, Manuel
    Shao, Zhimin
    Noguchi, Shinzaburo
    Rowbottom, Jacqui
    Stuart, Mary
    Grinsted, Lynda M.
    Fazal, Mehdi
    Ellis, Matthew J.
    LANCET, 2016, 388 (10063): : 2997 - 3005
  • [3] A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial)
    Coombes, R. C.
    Tovey, Holly
    Kilburn, Lucy
    Mansi, Janine
    Palmieri, Carlo
    Bartlett, John
    Hicks, Johnathon
    Makris, Andreas
    Evans, Abigail
    Loibl, Sibylle
    Denkert, Carsten
    Murray, Elisabeth
    Grieve, Robert
    Coleman, Robert
    Schmidt, Marcus
    Klare, Peter
    Rezai, Mahdi
    Rautenberg, Beate
    Klutinus, Nicole
    Rhein, Uwe
    Mousa, Kelly
    Ricardo-Vitorino, Susana
    von Minckwitz, Gunter
    Bliss, Judith
    CANCER RESEARCH, 2018, 78 (04)
  • [4] Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
    Masuda, Norikazu
    Sagara, Yasuaki
    Kinoshita, Takayuki
    Iwata, Hiroji
    Nakamura, Seigo
    Yanagita, Yasuhiro
    Nishimura, Reiki
    Iwase, Hirotaka
    Kamigaki, Shunji
    Takei, Hiroyuki
    Noguchi, Shinzaburo
    LANCET ONCOLOGY, 2012, 13 (04): : 345 - 352
  • [5] A multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial)
    Nabholtz, J-M A.
    Alsaleh, K. A.
    Bounedjar, A.
    Oukkal, M.
    El-Zawahry, H. M.
    Bouzid, K.
    Razek, H. Abdel
    Mahfouf, H.
    Bensalem, A.
    Saadeddin, A.
    Filali, T.
    Larbaoui, B.
    Abulkhair, O.
    Al-Foheidi, M.
    Boussen, H.
    Ayari, J.
    Ghosn, M.
    Abdel-Aziz, N.
    Dabouz, F.
    Kullab, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] REACT study: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients
    von Minckwitz, G.
    Conrad, B.
    Denkert, C.
    Eidtmann, H.
    Eiermann, W.
    Harbeck, W.
    Huober, J.
    Jackisch, C.
    Lueck, H.
    Moebus, V.
    Reimer, T.
    Rody, A.
    Stickeler, E.
    BREAST, 2009, 18 : S56 - S56
  • [7] FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer
    Ellis, M. J.
    Bondarenko, I.
    Trishkina, E.
    Dvorkin, M.
    Panasci, L.
    Manikhas, A.
    Shparyk, Y.
    Cardona-Huerta, S.
    Cheung, K-L.
    Philco-Salas, M. J.
    Ruiz-Borrego, M.
    Shao, Z.
    Noguchi, S.
    Grinsted, L. M.
    Fazal, M.
    Stuart, M.
    Robertson, J. F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomized Phase III trial
    Freeston, Sarah
    WOMENS HEALTH, 2012, 8 (02) : 123 - 124
  • [9] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
    Di Leo, Angelo
    Jerusalem, Guy
    Petruzelka, Lubos
    Torres, Roberto
    Bondarenko, Igor N.
    Khasanov, Rustem
    Verhoeven, Didier
    Pedrini, Jose L.
    Smirnova, Iya
    Lichinitser, Mikhail R.
    Pendergrass, Kelly
    Garnett, Sally
    Lindemann, Justin P. O.
    Sapunar, Francisco
    Martin, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) : 4594 - 4600
  • [10] Fadrozole versus megestrol acetate: A double-blind randomised trial in advanced breast cancer
    Bezwoda, WR
    Gudgeon, A
    Falkson, G
    Jordaan, JP
    Goedhals, L
    ONCOLOGY, 1998, 55 (05) : 416 - 420
12345